Experimental vaccine aims to stop melanoma recurrence in its tracks

NCT ID NCT01898039

Recruiting now Disease control Sponsor: Hadassah Medical Organization Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a vaccine made from modified melanoma cells in patients who had their tumors removed but are at high risk of recurrence. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells. Up to 50 participants will receive multiple injections over several months, with researchers monitoring safety and immune response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: A2/4-1BBL melanoma vaccine (M20/A2B cells)
What this could lead to: If successful, this vaccine could help prevent melanoma from coming back in patients at high risk of recurrence after tumor removal.
What could go wrong: This is an early phase I/II trial with only 50 participants, so results may not apply to all patients. The vaccine may cause side effects or fail to stimulate a strong enough immune response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma Neoplasm, Residual

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT MELANOMA

Contacts and locations

Locations

Sharett Institute of Oncology, Hadassah Medical Organization
RECRUITING

Jerusalem, 91120, Israel

More trials for these conditions

Other studies related to the condition(s) this trial covers.